Floatz logo

1-(18F)Fluoranyl-3-[[2-[(E)-4-[6-(methylamino)pyridin-3-yl]but-1-en-3-ynyl]-1,3-benzothiazol-6-yl]oxy]propan-2-ol

Alzheimer's Disease

JYAMS PET Research & Development LimitedSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
73/ 100

Competitive context

316 Active assets in the Alzheimer's Disease cohort.

Asset / SponsorPhaseRating
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE
Akiva Mintz
Phase 4BBB
Cipralex
NYU Langone Health
Phase 4BBB
Namenda
Carnot Laboratories
Phase 4BBB
FLORTAUCIPIR
Eli Radiopharma
Phase 4BBB
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)
Anhui Provincial Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

1-(18F)Fluoranyl-3-[[2-[(E)-4-[6-(methylamino)pyridin-3-yl]but-1-en-3-ynyl]-1,3-benzothiazol-6-yl]oxy]propan-2-ol is also rated in:

Healthy VolunteersDormant
BB
Indicative ·
64 / 100
View asset →
Alzheimer diseaseDormant
B
Indicative ·
60 / 100
View asset →
Neurofilament Light ChainDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →